Smoking cessation: How to advise the patient

Heart

Volumn 95, Issue 19, 2009, Pages 1635-1640

  Tonstad, Serena ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NICOTINE PATCH; VARENICLINE;

ATHEROSCLEROSIS; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE TITRATION; FOLLOW UP; HEALTH PROGRAM; HEALTH PROMOTION; HEART INFARCTION; HUMAN; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

AMBULATORY CARE; BEHAVIOR THERAPY; BENZAZEPINES; BUPROPION; COUNSELING; DOPAMINE UPTAKE INHIBITORS; HUMANS; MOTIVATION; NICOTINE; NICOTINIC AGONISTS; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; QUINOXALINES; RECURRENCE; SMOKING; SMOKING CESSATION;

EID: 70349451524     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.154476     Document Type: Review

References (20)

1. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006;113:2363-2372
2. Rigotti N, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers. Arch Intern Med 2008;168:1950-1960 Systematic review of the topic including 33 studies.
3. Dawood N, Vaccarino V, Reid KJ, et al, for the PREMIER Registry Investigators. Predictors of smoking cessation after a myocardial infarction. Arch Intern Med 2008;168:1961-1967 A prospective study done among 19 US hospitals showed that individual smoking cessation counselling was not associated with cessation post-myocardial infarction. Hospital based programmes and referral to cardiac rehabilitation were effective.
4. Scholte op Reimer W, de Swart E, De Bacquer D, et al, for the EUROASPIRE Investigators. Smoking behaviour in European patients with established coronary heart disease. Eur Heart J 2006;27:35-41.
5. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003;24:946-955 Study that demonstrates efficacy and safety of bupropion in patients with CVD. (Pubitemid 36559988)
6. Mohiuddin SM, Mooss AN, Hunter CB, et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 2007;131:446-452 A randomised, controlled study showing reduction in hospitalisation and mortality in patients with CVD treated intensively with post-hospital care and pharmacotherapy.
7. Rigotti N, Pipe A, Garza D, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. J Am Coll Cardiol 2009;53(Suppl. 1):A224. First study to demonstrate efficacy and safety of varenicline in patients with CVD.
8. Hatsukami DK, Stead LF, Gupta PC. Tobacco addiction. Lancet 2008;371:2027-2038 An authoritative update on tobacco addiction and cessation.
9. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003;46:91-111. A comprehensive review of the pathophysiology of smoking related CVD.
10. Rollnick S, Butler CC, Stott N. Helping smokers make decisions: the enhancement of brief intervention for general medical practice. Patient Educ Couns 1997;31:191-203. Description of motivational interviewing for smokers. (Pubitemid 27304292)
11. Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 2003;45:429-441 (Pubitemid 36666451)
12. Fiore MC. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. US Department of Health and Human Services, Public Health Service, May 2008. www.surgeongeneral. gov/tobacco/default.htm Authoritative US guidelines on clinical treatment.
13. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008:CD006103.
14. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial. Thorax 2008;63:717-724
15. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008;103:146-154 (Pubitemid 350233424)
16. McRobbie H, Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction 2001;96:1547-1551 (Pubitemid 33063455)
17. Rigotti NA, Thorndiake AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med 2006;119:1080-1087 (Pubitemid 44834365)
18. National Institute for Health and Clinical Evidence. NICE guidance on smoking cessation services. http://www.nice.org.uk/ Guidance/PH10. Authoritative guidance on behavioural and pharmacological therapies.
19. Rice VH, Stead LF. Nursing interventions for smoking cessation. Cochrane Database Syst Rev 2004;1:CD001188.
20. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71.